Janssen Signs an Agreement with Celsius Therapeutics to Identify Response Biomarkers for Ulcerative Colitis

Shots:

• Celsius to receive payments and milestones based on the use of biomarkers identified, holding the rights to integrate the data generated from the study into its database of patient and single-cell genomic information further interrogating it for its own target and drug discovery
• Janssen to utilize Celsius’ single-cell genomics and machine learning platformto identify response biomarkers from P-II VEGA study assessing guselkumab and golimumab in patients with UC
• Celsius and Janssen will extract deep molecular and cellular insights from the generated data, leading to better QoL. Guselkumab (marketed as Tremfya) is a mAb indicated for plaque psoriasis whereas Golimumab (marketed as Simponi) is a TNF inhibitor indicated for UC

Click here to read full press release/ article | Ref: Celsius Therapeutics | Image: Owler